Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): An international systematic review and meta‐analysis-Reference-Cited by-同舟云学术

Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): An international systematic review and meta‐analysis

Published:2020-03-03 Issue:10 Volume:126 Page:2120-2131
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Tchelebi Leila T.¹^ORCID,Lehrer Eric J.²^ORCID,Trifiletti Daniel M.³^ORCID,Sharma Navesh K.¹,Gusani Niraj J.⁴⁵^ORCID,Crane Christopher H.⁶,Zaorsky Nicholas G.¹⁵^ORCID

Affiliation:

1. Department of Radiation Oncology Penn State Cancer Institute Hershey Pennsylvania

2. Department of Radiation Oncology Icahn School of Medicine at Mount Sinai New York New York

3. Department of Radiation Oncology Mayo Clinic Jacksonville Florida

4. Department of Surgery Penn State College of Medicine Hershey Pennsylvania

5. Department of Public Health Sciences Penn State College of Medicine Hershey Pennsylvania

6. Department of Radiation Oncology Memorial Sloan Kettering Cancer Center New York New York

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32756

Reference50 articles.

1. American Cancer Society.Survival rates for pancreatic cancer. Accessed August 20 2019.https://www.cancer.org/cancer/pancreatic-cancer/detection-diagnosis-staging/survival-rates.html

2. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study.

3. Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial

4. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study

5. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stereotactic Magnetic Resonance-Guided Daily Adaptive SABR (SMART) for Localised Non-Metastatic Pancreatic Cancer: First Reported Clinical Outcomes From the UK;Clinical Oncology;2024-09

2. Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial;European Journal of Cancer;2024-09

3. Radiation therapy for locally advanced pancreatic adenocarcinoma: a therapeutic option which should not be forgotten. Letter to the Editor regarding: “Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up” by Huguet et al.;Annals of Oncology;2024-08

4. Guidelines for holistic integrative management of pancreatic cancer;Holistic Integrative Oncology;2024-07-08

5. Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer;Clinical and Experimental Gastroenterology;2024-07